These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 33795694)

  • 1. Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response.
    Madsen A; Jul-Larsen Å; Trieu MC; Krammer F; Cox RJ
    NPJ Vaccines; 2021 Apr; 6(1):45. PubMed ID: 33795694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study.
    Trieu MC; Jul-Larsen Å; Sævik M; Madsen A; Nøstbakken JK; Zhou F; Skrede S; Cox RJ
    Clin Infect Dis; 2019 Jan; 68(3):382-392. PubMed ID: 29893797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented CD4
    Trieu MC; Zhou F; Lartey SL; Sridhar S; Mjaaland S; Cox RJ
    NPJ Vaccines; 2018; 3():37. PubMed ID: 30131880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination.
    Madsen A; Azimi L; Tete S; Zhou F; Krammer F; Cox RJ; Jul-Larsen Å
    Vaccine X; 2019 Aug; 2():100029. PubMed ID: 31384744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014).
    Amdam H; Madsen A; Zhou F; Bansal A; Trieu MC; Cox RJ
    Front Immunol; 2021; 12():748281. PubMed ID: 34938285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responses to live attenuated influenza vaccine in children vaccinated previously with Pandemrix (ASO3
    Höschler K; Southern J; Thompson C; Warburton F; Andrews NJ; Miller E; Zambon M
    Vaccine; 2018 May; 36(21):3034-3040. PubMed ID: 29680198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.
    Ferguson M; Risi G; Davis M; Sheldon E; Baron M; Li P; Madariaga M; Fries L; Godeaux O; Vaughn D
    J Infect Dis; 2012 Mar; 205(5):733-44. PubMed ID: 22315336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of anti-NS1 antibodies after pandemic influenza exposure: Evaluation of a serological method for distinguishing H1N1pdm09 infected from vaccinated cases.
    Robertson AH; Mahic M; Savic M; Tunheim G; Hungnes O; Trogstad L; Lipkin WI; Mjaaland S
    Influenza Other Respir Viruses; 2020 May; 14(3):294-301. PubMed ID: 31955522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
    Saitoh A; Nagai A; Tenjinbaru K; Li P; Vaughn DW; Roman F; Kato T
    Hum Vaccin Immunother; 2012 Jun; 8(6):749-58. PubMed ID: 22495117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.
    Nachbagauer R; Kinzler D; Choi A; Hirsh A; Beaulieu E; Lecrenier N; Innis BL; Palese P; Mallett CP; Krammer F
    NPJ Vaccines; 2016; 1():16015-. PubMed ID: 29250436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination.
    Tete SM; Krammer F; Lartey S; Bredholt G; Wood J; Skrede S; Cox RJ
    NPJ Vaccines; 2016; 1():16001-. PubMed ID: 29250435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.
    Luytjes W; Enouf V; Schipper M; Gijzen K; Liu WM; van der Lubben M; Meijer A; van der Werf S; Soethout EC
    Vaccine; 2012 Jul; 30(35):5262-9. PubMed ID: 22691431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-associated enhanced respiratory disease does not interfere with the adaptive immune response following challenge with pandemic A/H1N1 2009.
    Gauger PC; Loving CL; Lager KM; Janke BH; Kehrli ME; Roth JA; Vincent AL
    Viral Immunol; 2013 Oct; 26(5):314-21. PubMed ID: 24033080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
    Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
    PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.